EPKINLYの薬剤に関する洞察と市場予測：2032年

EPKINLY（別名エプコリタマブ、GEN3013）は、Genmab独自のDuoBody技術を用いて創製されたIgG1二重特異性抗体です。Genmab社のDuoBody-CD3技術は、細胞傷害性T細胞を選択的に誘導し、標的細胞種に対する免疫応答を誘発します。エプコリタマブは、T細胞のCD3およびB細胞のCD20に結合し、T細胞を介したCD20+細胞の殺傷を誘導するように設計されています。

エプコリタマブは、AbbVieとGenmabのがん領域における共同研究の一環として共同開発されています。両社は米国と日本における商業的責任を分担し、AbbVieはさらなる世界な商業化を担当します。両社は、エプコリタマブの単剤療法および併用療法について、さまざまな血液悪性腫瘍の治療ライン全体で評価することにコミットしています。これには、R/R DLBCL患者を対象にエプコリタマブ単剤療法を評価する進行中の第III相非盲検無作為化臨床試験や、R/R FL患者を対象にエプコリタマブ併用療法を評価する第III相非盲検臨床試験が含まれます。

当レポートでは、主要7ヶ国におけるEPKINLY市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 DLBCLのEPKINLYの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 EPKINLY市場評価

• DLBCLに対するEPKINLYの市場見通し
• 主要7ヶ国分析
  • 主要7ヶ国におけるDLBCLに対するEPKINLYの市場規模
• 国別の市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

• 参考文献
• レポート調査手法

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: EPKINLY, Clinical Trial Description, 2023
• Table 2: EPKINLY, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: EPKINLY Market Size in the 7MM, in USD million (2019-2032)
• Table 6: EPKINLY Market Size in the US, in USD million (2019-2032)
• Table 7: EPKINLY Market Size in Germany, in USD million (2019-2032)
• Table 8: EPKINLY Market Size in France, in USD million (2019-2032)
• Table 9: EPKINLY Market Size in Italy, in USD million (2019-2032)
• Table 10: EPKINLY Market Size in Spain, in USD million (2019-2032)
• Table 11: EPKINLY Market Size in the UK, in USD million (2019-2032)
• Table 12: EPKINLY Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: EPKINLY Market Size in the 7MM, USD million (2019-2032)
• Figure 2: EPKINLY Market Size in the United States, USD million (2019-2032)
• Figure 3: EPKINLY Market Size in Germany, USD million (2019-2032)
• Figure 4: EPKINLY Market Size in France, USD million (2019-2032)
• Figure 5: EPKINLY Market Size in Italy, USD million (2019-2032)
• Figure 6: EPKINLY Market Size in Spain, USD million (2019-2032)
• Figure 7: EPKINLY Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: EPKINLY Market Size in Japan, USD million (2019-2032)

"EPKINLY Drug Insight and Market Forecast - 2032" report provides comprehensive insights about EPKINLY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets. A detailed picture of the EPKINLY for DLBCL in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the EPKINLY for DLBCL. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EPKINLY market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.

Drug Summary:

EPKINLY (also known as Epcoritamab, GEN3013) is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology. Genmab's DuoBody-CD3 technology directs cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to bind to CD3 on T cells and CD20 on B cells and induce T-cell mediated killing of CD20+ cells.

Epcoritamab is being codeveloped by AbbVie and Genmab as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the US and Japan, with AbbVie responsible for further global commercialization. The companies are committed to evaluating epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes an ongoing Phase III, open-label, randomized clinical trial evaluating epcoritamab as a monotherapy in patients with R/R DLBCL and a Phase III, open-label clinical trial evaluating epcoritamab in combination in patients with R/R FL.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the EPKINLY description, mechanism of action, dosage and administration, research and development activities in Diffuse Large B-cell lymphoma (DLBCL).
• Elaborated details on EPKINLY regulatory milestones and other development activities have been provided in this report.
• The report also highlights the EPKINLY research and development activities in DLBCL across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around EPKINLY.
• The report contains forecasted sales of EPKINLY for DLBCL till 2032.
• Comprehensive coverage of the late-stage emerging therapies for DLBCL.
• The report also features the SWOT analysis with analyst views for EPKINLY in DLBCL.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EPKINLY Analytical Perspective by DelveInsight

In-depth EPKINLY Market Assessment

This report provides a detailed market assessment of EPKINLY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

EPKINLY Clinical Assessment

The report provides the clinical trials information of EPKINLY for DLBCL covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Diffuse Large B-cell lymphoma (DLBCL) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EPKINLY dominance.
• Other emerging products for DLBCL are expected to give tough market competition to EPKINLY and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EPKINLY in DLBCL.
• Our in-depth analysis of the forecasted sales data of EPKINLY from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EPKINLY in DLBCL.

Key Questions:

• What is the product type, route of administration and mechanism of action of EPKINLY?
• What is the clinical trial status of the study related to EPKINLY in Diffuse Large B-cell lymphoma (DLBCL) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EPKINLY development?
• What are the key designations that have been granted to EPKINLY for DLBCL?
• What is the forecasted market scenario of EPKINLY for DLBCL?
• What are the forecasted sales of EPKINLY in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to EPKINLY for DLBCL?
• Which are the late-stage emerging therapies under development for the treatment of DLBCL?

Table of Contents

1. Report Introduction

2. EPKINLY Overview in DLBCL

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. EPKINLY Market Assessment

• 5.1. Market Outlook of EPKINLY in DLBCL
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of EPKINLY in the 7MM for DLBCL
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of EPKINLY in the United States for DLBCL
  • 5.3.2. Market Size of EPKINLY in Germany for DLBCL
  • 5.3.3. Market Size of EPKINLY in France for DLBCL
  • 5.3.4. Market Size of EPKINLY in Italy for DLBCL
  • 5.3.5. Market Size of EPKINLY in Spain for DLBCL
  • 5.3.6. Market Size of EPKINLY in the United Kingdom for DLBCL
  • 5.3.7. Market Size of EPKINLY in Japan for DLBCL

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options